Overview

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Status:
Completed
Trial end date:
2002-12-31
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Busulfan
Cyclophosphamide
Cyclosporine
Cyclosporins
Decitabine
Methotrexate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Tacrolimus
Criteria
DISEASE CHARACTERISTICS: Acute leukemia past first remission or induction failure Chronic
myelogenous leukemia in accelerated phase or blast crisis

PATIENT CHARACTERISTICS: Age: 15 to 55 Performance status: Zubrod 0-2 Life expectancy: Life
expectancy not severely limited by concurrent illness Hematopoietic: Not specified Hepatic:
No evidence of chronic active hepatitis or cirrhosis Bilirubin no greater than 2 times
upper limit of normal SGPT no greater than 4 times upper limit of normal Renal: Creatinine
no greater than 1.5 mg/dL Cardiovascular: Left ventricular ejection fraction at least 50%
No uncontrolled arrhythmias or symptomatic cardiac disease Pulmonary: FEV1, FVC, and DLCO
at least 50% No symptomatic pulmonary disease Other: Related donor who is HLA-identical
required No effusion or ascites greater than 1 L prior to drainage HIV negative Not
pregnant No active CNS disease

PRIOR CONCURRENT THERAPY: Not specified